In early research, Retatrutide has shown some of the strongest weight-loss results to date, along with improvements in blood sugar, liver fat, and overall metabolic health
References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1
Tresiba and GLP-1 combination therapy While Tresiba is not a GLP-1, the two drug classes are frequently prescribed together
But its not expected to get FDA approval until 2027, she said
While some medications can be delivered through the skinsuch as estrogen patches used in hormone therapythere are currently no weight loss patches on the market that contain FDA-approved ingredients
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy for adults with obesity